This story originally ran on Nov. 17.
AB Sciex said this week it has acquired Indian life sciences services provider Labindia's mass spectrometry division.
The deal, which stems from an ongoing partnership between the two companies, will expand AB Sciex's footprint in the fast-growing Indian market, "allowing the company to engage in a new level of dialogue with Indian scientists," Umesh Pawa, managing director of AB Sciex India, said in a statement.
Labindia's offerings include a variety of proteomics services, including LC-MS and biomarker discovery work. According to Pawa, demand for proteomics research is growing in India, with much of it focused on biomarker discovery and plant proteomics.
"Protein biomarker discovery is in full swing in India," he told ProteoMonitor, noting that tropical infectious diseases and oncology were particular areas of focus.
"There's also significant [work] going on in plant proteomics, because a large portion of the Indian economy is dependent on agriculture," Pawa said.
Most of India's proteomics research is government funded, he said, with support coming from bodies including the Department of Science and Technology, the Department of Biotechnology, and the National Institute of Plant Genome Research.
"The majority of [India's] proteomics market revolves around [such] research institutes, followed by academia," he said.
While private firms including drug companies have begun to incorporate proteomics, they still represent a small portion of the market, Pawa said.
"Pharma in India is still a little ways from [widespread use of] proteomics applications," he said. "Almost all pharma companies have some amount of proteomics work going on, but I wouldn't compare it to the levels in the United States or Europe."
Financial terms of the agreement were not released.
Have topics you'd like to see covered in ProteoMonitor? Contact the editor at abonislawski [at] genomeweb [.] com.